About the Trial
An investigational minimally invasive treatment to help reduce blood pressure is now being studied. Patients with high blood pressure who are currently taking anti-hypertensive medications and who are otherwise healthy might qualify to participate in the TARGET BP I Clinical Trial.
The TARGET BP I Clinical Trial is evaluating the Peregrine System™ Kit which is used in a minimally invasive procedure with the goal of reducing blood pressure by deactivating specific nerves surrounding the renal (kidney) arteries that, through over-signaling, can contribute to high blood pressure. Patients will continue taking anti-hypertensive medications during the study.
The procedure is performed under mild sedation. The Peregrine Catheter will be advanced through a small incision in the groin and guided up to the renal arteries using angiography (like an X- ray). The system will deliver a small dose of Ablative Solutions medical alcohol to the region just outside the artery where these sympathetic nerves are located, to deactivate their over-signaling. The approach has been previously used in early studies with the Peregrine Catheter.(6,7)